Biophytis (EPA:ALBPS)

BRIEF

published on 04/08/2024 at 23:15, 1 year 9 months ago

Biophytis Initiates Phase 2 Clinical Study for Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 GLP-1 Receptor Agonists OBA Phase 2 Study
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 1 year 9 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations

Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 1 year 9 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
BRIEF

published on 04/08/2024 at 23:09, 1 year 9 months ago

Biophytis announces its 2023 financial results and provides an update on its activities

Biophytis Funding Clinical Development 2023 Financial Results BIO101
BRIEF

published on 04/08/2024 at 23:05, 1 year 9 months ago

Biophytis Announces Phase 2 Clinical Study in Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 OBA Phase 2 Clinical Study GLP-1 Receptor Agonists
PRESS RELEASE

published on 04/08/2024 at 23:04, 1 year 9 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
PRESS RELEASE

published on 04/08/2024 at 23:01, 1 year 9 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE

published on 04/08/2024 at 23:00, 1 year 9 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024

Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
BRIEF

published on 04/04/2024 at 23:05, 1 year 9 months ago

Biophytis Announces Unanimous Approval in General Meeting

Biophytis Shareholder Approval General Meeting RuvembriTM Age-related Diseases
PRESS RELEASE

published on 04/04/2024 at 23:00, 1 year 9 months ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces all resolutions presented at the combined general meeting on April 2, 2024, have been adopted, including financial delegations. Shareholders' mobilization ensured a quorum of nearly 30%

Shareholders Biophytis General Meeting Resolutions Approval

Published on 01/31/2026 at 03:15, 2 hours 10 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 3 hours 5 minutes ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 3 hours 45 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 5 hours 25 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 6 hours 25 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 02:45, 2 hours 39 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 7 hours 25 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 9 hours 14 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 9 hours 15 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 9 hours 17 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches

View all EQS

Published on 01/30/2026 at 17:45, 11 hours 40 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 21 hours 25 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 11 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 11 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 11 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News